James Abbruzzese, MD

Professor of Medicine
D. C. I. Professor of Medical Oncology
Chief, Division of Medical Oncology
Member of the Duke Cancer Institute
Campus mail 440 Mudd Building, Box 3406, Durham, NC 27710
Email address james.abbruzzese@duke.edu

My research interests include the clinical study and treatment of pancreatic cancer.

In Their Words

Education and Training

  • Resident, Internal Medicine, Johns Hopkins University School of Medicine, 1979 - 1981
  • Intern, Internal Medicine, Johns Hopkins University School of Medicine, 1978 - 1979
  • M.D., University of Chicago, 1978

Publications

Abbruzzese, J. L., C. F. Gholson, K. Daugherty, E. Larson, R. DuBrow, R. Berlin, and B. Levin. “A pilot clinical trial of the cholecystokinin receptor antagonist MK-329 in patients with advanced pancreatic cancer..” Pancreas 7, no. 2 (1992): 165–71.

PMID
1553366
Scholars@Duke

Abbruzzese, J. L., and P. P. Carbone. “Adenocarcinoma of the liver without a detectable primary..” Hosp Pract (Off Ed) 26, no. 12 (December 15, 1991): 61-passim.

PMID
1744188
Scholars@Duke

Ajani, J. A., R. Pazdur, R. J. Winn, J. L. Abbruzzese, B. Levin, R. Belt, J. Young, Y. Z. Patt, and I. H. Krakoff. “Phase II study of intravenous 6-thioguanine in patients with advanced carcinoma of the pancreas..” Invest New Drugs 9, no. 4 (November 1991): 369–71.

PMID
1804816
Scholars@Duke

Linke, K., R. Pazdur, J. L. Abbruzzese, J. A. Ajani, R. Winn, J. E. Bradof, K. Daugherty, and B. Levin. “Phase II study of amonafide in advanced pancreatic adenocarcinoma..” Invest New Drugs 9, no. 4 (November 1991): 353–56.

PMID
1804812
Scholars@Duke

Lee, N. K., R. M. Byers, J. L. Abbruzzese, and P. Wolf. “Metastatic adenocarcinoma to the neck from an unknown primary source..” Am J Surg 162, no. 4 (October 1991): 306–9. https://doi.org/10.1016/0002-9610(91)90137-3.

PMID
1951879
Full Text

Ajani, J. A., R. Pazdur, R. J. Winn, J. L. Abbruzzese, B. Levin, C. Wiseman, M. A. Lenado-Lee, Y. Z. Patt, and I. H. Krakoff. “Phase II study of intravenous 6-thioguanine in patients with advanced gastric carcinoma..” Invest New Drugs 9, no. 3 (August 1991): 257–59.

PMID
1783525
Scholars@Duke

Raber, M. N., J. Faintuch, J. L. Abbruzzese, C. Sumrall, and P. Frost. “Continuous infusion 5-fluorouracil, etoposide and cis-diamminedichloroplatinum in patients with metastatic carcinoma of unknown primary origin..” Ann Oncol 2, no. 7 (July 1991): 519–20. https://doi.org/10.1093/oxfordjournals.annonc.a058007.

PMID
1911461
Full Text

Abbruzzese, J. L., R. Grunewald, E. A. Weeks, D. Gravel, T. Adams, B. Nowak, S. Mineishi, P. Tarassoff, W. Satterlee, and M. N. Raber. “A phase I clinical, plasma, and cellular pharmacology study of gemcitabine..” J Clin Oncol 9, no. 3 (March 1991): 491–98. https://doi.org/10.1200/JCO.1991.9.3.491.

PMID
1999720
Full Text

Grunewald, R., J. L. Abbruzzese, P. Tarassoff, and W. Plunkett. “Saturation of 2',2'-difluorodeoxycytidine 5'-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine..” Cancer Chemother Pharmacol 27, no. 4 (1991): 258–62.

PMID
1998982
Scholars@Duke

Pazdur, R., J. A. Ajani, Y. Z. Patt, R. Winn, D. Jackson, B. Shepard, R. DuBrow, L. Campos, M. Quaraishi, and J. Faintuch. “Phase II study of fluorouracil and recombinant interferon alfa-2a in previously untreated advanced colorectal carcinoma..” J Clin Oncol 8, no. 12 (December 1990): 2027–31. https://doi.org/10.1200/JCO.1990.8.12.2027.

PMID
2230894
Full Text

Pages